Growth hormone deficiency drug from OPKO and Pfizer fails study

(Reuters) – OPKO Health Inc said its experimental drug for growth hormone deficiency (GHD) in adults failed to provide a statistically significant benefit over a placebo in a late-stage study, sending its shares down about 17 percent on Friday.


Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *